The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2023 | Lymphoid aggregates as a potential prognostic factor for MDS
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, comments on the results of a study evaluating the impact of bone marrow lymphoid aggregates in patients with myelodysplastic syndromes (MDS). The study indicated that patients with MDS had lymphoid aggregates more frequently than controls, and these appeared to be associated with the presence of other poor prognostic factors, thus highlighting its potential as a novel prognostic marker.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Research Funding; Takeda: Honoraria, Research Funding; Janssen: Research Funding; Roche: Research Funding; BMS: Research Funding; Celgene: Research Funding; Medison: Research Funding; Gilead: Research Funding.
